Given that use of GLP-1 RAs have been associated with muscle loss, an important question that remains is whether repeated GLP-1 RA use and cessation alter body composition in favour of fat mass relative to lean mass, pushing individuals with obesity closer to sarcopenic obesity. The gene discussed is GLP1R; the disease is obesity disorder.